1
|
Heart rate variability (HRV): From brain death to resonance breathing at 6 breaths per minute. Clin Neurophysiol 2020; 131:676-693. [DOI: 10.1016/j.clinph.2019.11.013] [Citation(s) in RCA: 50] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2019] [Revised: 10/14/2019] [Accepted: 11/06/2019] [Indexed: 12/13/2022]
|
2
|
Berdat PA, Gygax E, Nydegger U, Carrel T. Short- and long-term mechanical cardiac assistance. Int J Artif Organs 2018. [DOI: 10.1177/039139880102400504] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
With the increase in high risk patients undergoing cardiac surgery and the substantial mortality among patients waiting for cardiac transplantation, the need for mechanical circulatory support is growing. Several devices are currently available, ranging from the intra-aortic balloon pump to fully implantable ventricular assist devices. Each system has its own features, and proper patient selection as well as the timing of implantation is sometimes difficult. Algorithms for stepwise management in subgroups of patients remain controversial and the concepts of weaning patients after myocardial recovery during mechanical circulatory support need further evaluation for their long-term effects. Future identification of valuable prognostic and risk factors may help in decision-making and allow for improved survival of these often very ill patients. In this report we review the concepts of mechanical circulatory support at our institution with emphasis on a detailed overview of technical features of extracorporeal life support.
Collapse
Affiliation(s)
- P. A. Berdat
- Department of Cardiovascular Surgery, University Hospital, Bern - Switzerland
| | - E. Gygax
- Department of Cardiovascular Surgery, University Hospital, Bern - Switzerland
| | - U. Nydegger
- Department of Cardiovascular Surgery, University Hospital, Bern - Switzerland
| | - T. Carrel
- Department of Cardiovascular Surgery, University Hospital, Bern - Switzerland
| |
Collapse
|
3
|
Abstract
Left ventricular assist devices (LVADs) are an effective therapy for a growing and aging population in the background of limited donor supply. Selecting the proper patient involves assessment of indications, risk factors, scores for overall outcomes, assessment for right ventricular failure, and optimal timing of implantation. LVAD complications have a 5% to 10% perioperative mortality and complications of bleeding, thrombosis, stroke, infection, right ventricular failure, and device failure. As LVAD engineering technology evolves, so will the risk-prediction scores. Hence, more large-scale prospective data from multicenters will continually be required to aid in patient selection, reduce complications, and improve long-term outcomes.
Collapse
|
4
|
Left Ventricular Assist Devices: Challenges Toward Sustaining Long-Term Patient Care. Ann Biomed Eng 2017; 45:1836-1851. [DOI: 10.1007/s10439-017-1858-9] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Accepted: 05/22/2017] [Indexed: 11/25/2022]
|
5
|
Sohrabi S, Liu Y. A Cellular Model of Shear-Induced Hemolysis. Artif Organs 2017; 41:E80-E91. [PMID: 28044355 DOI: 10.1111/aor.12832] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Revised: 06/12/2016] [Accepted: 07/19/2016] [Indexed: 12/13/2022]
Abstract
A novel model is presented to study red blood cell (RBC) hemolysis at cellular level. Under high shear rates, pores form on RBC membranes through which hemoglobin (Hb) leaks out and increases free Hb content of plasma leading to hemolysis. By coupling lattice Boltzmann and spring connected network models through immersed boundary method, we estimate hemolysis of a single RBC under various shear rates. First, we use adaptive meshing to find local strain distribution and critical sites on RBC membranes, and then we apply underlying molecular dynamics simulations to evaluate damage. Our approach comprises three sub-models: defining criteria of pore formation, calculating pore size, and measuring Hb diffusive flux out of pores. Our damage model uses information of different scales to predict cellular level hemolysis. Results are compared with experimental studies and other models in literature. The developed cellular damage model can be used as a predictive tool for hydrodynamic and hematologic design optimization of blood-wetting medical devices.
Collapse
Affiliation(s)
| | - Yaling Liu
- Department of Mechanical Engineering & Mechanics.,Bioengineering Program, Lehigh University, Bethlehem, PA, USA
| |
Collapse
|
6
|
Capoccia M, Bowles CT, Sabashnikov A, De Robertis F, Amrani M, Banner NR, Simon A. A UK Single Centre Retrospective Analysis of the Relationship between Haemodynamic Changes and Outcome in Patients Undergoing Prolonged Left Ventricular Assist Device Support. Ann Thorac Cardiovasc Surg 2014; 21:151-6. [PMID: 25017117 DOI: 10.5761/atcs.oa.14-00075] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
PURPOSE Despite their efficacy, LVADs remain associated with serious complications. The relationship between haemodynamic changes during support and outcome remains inadequately characterised. This association was investigated in LVAD recipients undergoing prolonged support. METHODS Forty patients receiving LVAD therapy for >2 years were reviewed retrospectively (mean support duration was 38.62 ± 15.28). Pre- and on-LVAD haemodynamic data were assessed in three groups: (1) those receiving ongoing support (n = 24); (2) those who underwent cardiac transplantation (n = 4); (3) those who died during support (n = 12). RESULTS For group 1 and 2, LVAD support achieved a decrease in mean PAP, mean PCWP, TPG, and PVR and an increase in thermodilution blood flow (TBF) with significance at ≤5% level. For group 3, there were non-significant changes in TPG and PVR at the 5% level but for mean PAP, mean PCWP, and TBF the changes were similar to Groups 1 and 2 with significance at ≤5% level. Aggregated data from all three groups showed a 58% increase in TBF on LVAD support. CONCLUSION Highly significant and favourable haemodynamic changes were found. However, group 3 did not undergo decrease in TPG and PVR possibly because of suboptimal LVAD flow, right heart dysfunction and unavoidable prolongation of support.
Collapse
Affiliation(s)
- Massimo Capoccia
- Department of Cardiothoracic Surgery, Transplantation & Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, UK
| | | | | | | | | | | | | |
Collapse
|
7
|
SU BOYANG, CHUA LEOKPOH, ZHONG LIANG. NUMERICAL STUDIES OF AN AXIAL FLOW BLOOD PUMP WITH DIFFERENT DIFFUSER DESIGNS. J MECH MED BIOL 2013. [DOI: 10.1142/s0219519413500292] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Most axial flow blood pumps basically consist of a straightener, an impeller, and a diffuser. The diffuser plays a very important role in the performance of the pump to provide an adequate pressure head and to increase the hydraulic efficiency. During the development of an axial flow blood pump, irregular flow field near the diffuser hub is not desirable as it may induce thrombosis. In order to avoid this phenomenon, two approaches were adopted. In the first approach, the number of the diffuser blades was increased from three (B3, baseline model) to five (B5 model). It was observed that the flow field was improved, but the irregular flow patterns were not completely eliminated. In the second approach, we detached the blades from the diffuser hub (B3C2 model), which was integrated and rotated with the impeller hub. It was found that the rotary diffuser hub significantly improved the flow field, especially near the diffuser hub. Besides the detailed flow fields, the hydraulic and hematologic performances at various flow conditions were also estimated using computational fluid dynamics (CFD). Although each design has its own advantages and disadvantages, the B5 model was superior based on a comparative overview.
Collapse
Affiliation(s)
- BOYANG SU
- Department of Bioengineering, National University of Singapore, 9 Engineering Drive 1, Singapore 117575, Singapore
| | - LEOK POH CHUA
- School of Mechanical and Aerospace Engineering, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798, Singapore
| | - LIANG ZHONG
- Cardiac Mechanics Engineering and Physiology Unit, Department of Cardiology, National Heart Centre Singapore, 17 Third Hospital Avenue, Mistri Wing, Singapore 168752, Singapore
| |
Collapse
|
8
|
Timms D. A review of clinical ventricular assist devices. Med Eng Phys 2011; 33:1041-7. [PMID: 21665512 DOI: 10.1016/j.medengphy.2011.04.010] [Citation(s) in RCA: 99] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2010] [Revised: 04/18/2011] [Accepted: 04/23/2011] [Indexed: 11/18/2022]
Abstract
Given the limited availability of donor hearts, ventricular assist device (VAD) therapy is fast becoming an accepted alternative treatment strategy to treat end-stage heart failure. The field of mechanical ventricular assistance is littered with novel and unique ideas either based on volume displacement or rotary pump technology, which aim to sufficiently restore cardiac output. However, only a select few have made the transition to the clinical arena. Clinical implants were initially dominated by the FDA approved volume displacement Thoratec HeartMate I, IVAD, and PVAD, whilst Berlin Heart's EXCOR, and Abiomed's BVS5000 and AB5000 offered suitable alternatives. However, limitations associated with an inherently large size and reduced lifetime of these devices stimulated the development and subsequent implantation of rotary blood pump (RBP) technology. Almost all of the reviewed RBPs are clinically available in Europe, whilst many are still undergoing clinical trial in the USA. Thoratec's HeartMate II is currently the only rotary device approved by the FDA, and has supported the highest number of patients to date. This pump is joined by MicroMed Cardiovascular's Heart Assist 5 Adult VAD, Jarvik Heart's Jarvik 2000 FlowMaker and Berlin Heart's InCOR as the axial flow devices under investigation in the USA. More recently developed radial flow devices such as WorldHeart's Levacor, Terumo's DuraHeart, and HeartWare's HVAD are increasing in their clinical trial patient numbers. Finally CircuLite's Synergy and Abiomed's Impella are two mixed flow type devices designed to offer partial cardiac support to less sick patients. This review provides a brief overview of the volume displacement and rotary devices which are either clinically available, or undergoing the advanced stages of human clinical trials.
Collapse
Affiliation(s)
- Daniel Timms
- ICET Laboratory, Critical Care Research Group, The Prince Charles Hospital and University of Queensland, Brisbane, Australia.
| |
Collapse
|
9
|
Abstract
Ventricular assist devices are an important therapeutic option for advanced congestive heart failure. A left ventricular assist device (LVAD) can be implanted as a bridge to transplantation or for the purpose of destination therapy. LVADs improve end-organ function and reduce morbidity and mortality in appropriately selected patients. The development of axial flow pumps has overcome many of the limitations of the first-generation pulsatile flow LVADs. However, many complications of LVAD therapy remain. Treating these complications requires an understanding of LVAD physiology. Ongoing research is directed at reducing the incidence of many of these complications and may allow for wider use of LVADs.
Collapse
Affiliation(s)
- Gabriel Sayer
- The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA
| | | | | |
Collapse
|
10
|
Mathier MA, Murali S. Cardiac Transplantation and Circulatory Support Devices. Cardiovasc Ther 2007. [DOI: 10.1016/b978-1-4160-3358-5.50024-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
11
|
Son HS, Sun K, Hwang CM, Fang YH, Lim CH, Lee HW, Park SM, Shin JS, Kim KT, Kim HM. Ventricular Assist Device Implantation Using a Right Thoracotomy. ASAIO J 2006; 52:386-90. [PMID: 16883117 DOI: 10.1097/01.mat.0000227692.75032.86] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Most patients needing implantation of a ventricular assist device (VAD) require repeated sternotomy; some after cardiac surgery, and others later for heart transplantation. The purpose of this study was to establish the right thoracotomy technique as an alternative for VAD implantation to reduce repeated sternotomy-related morbidity and mortality. We performed a right thoracotomy in animals, preclinical cadaver fitting tests, and a clinical case. A total of 20 various animals underwent right thoracotomy for implantation of bi-VAD (BVAD, n = 17) and left VAD (LVAD, n = 3). The right chest cavity was entered through the fourth intercostal space with partial resection of the fifth rib. There was no procedure-related morbidity or mortality, except for one calf with right anterior leg paralysis. Preclinical fitting tests were performed on 7 human cadavers to observe the anatomical feasibility of BVAD cannulation from the right side of the heart. In humans, the ascending aorta, interatrial groove, right atrium, and main pulmonary artery were identified as optimal cannula insertion sites for BVAD implantation. A patient with cardiogenic shock underwent a right thoracotomy for implantation of an external LVAD. Cardiac function recovered after 3 weeks, and the device was successfully explanted through a repeat right thoracotomy. In conclusion, a right thoracotomy can be an alternative method to the standard median sternotomy for patients who need repeated sternotomy because of previous cardiac surgery, transplantation at a later date, or those with mediastinal infections.
Collapse
Affiliation(s)
- Ho Sung Son
- Department of Thoracic and Cardiovascular Surgery, Korea University, Seoul, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
|
13
|
He P, Bai J, Xia DD. Optimum control of the Hemopump as a left-ventricular assist device. Med Biol Eng Comput 2005; 43:136-41. [PMID: 15742732 DOI: 10.1007/bf02345135] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
A general framework for designing an optimum control strategy for the Hemopump is described. An objective function was defined that includes four membership functions, each constructed based on the desired values of one of the four members: stroke volume, mean left atrial pressure, aortic diastolic pressure and mean pump rotation speed. The Hemopump was allowed to operate either at a constant speed or at two different speeds during a cardiac cycle. The goal was to maximise the objective function by varying the magnitude and timing of the pump speed. Using a canine circulatory model, it was demonstrated that, in general, different cardiac conditions or different clinical objectives require different operation parameters. For example, when a left ventricle with minor ischaemia was simulated, and the main objective was to increase stoke volume, the objective function was maximised, from a value of 0.877 when the pump was off, to 0.946 when the pump was operated at speed 2 (18 500 revolutions min(-1)). On the other hand, for a severely ischaemic heart, the optimum pump speed became speed 3 (20 000 revolutions min(-1)), which maximized the objective function to 0.943 (from 0.707 when the pump was off). The results also suggest that it is more beneficial to operate the Hemopump at two different speeds during a cardiac cycle (a higher speed during systole and early diastole, and a lower speed during late diastole) than to maintain a constant speed throughout the cardiac cycle.
Collapse
Affiliation(s)
- P He
- Department of Biomedical, Industrial & Human Factors Engineering, Wright State University, Dayton, Ohio, USA.
| | | | | |
Collapse
|
14
|
Morgan JA, Mazzeo PA, Flannery MR, Oz MC, Naka Y. Effects of changes in UNOS policy regarding left ventricular assist devices. J Heart Lung Transplant 2004; 23:620-2. [PMID: 15135380 DOI: 10.1016/s1053-2498(03)00302-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2003] [Revised: 05/12/2003] [Accepted: 06/04/2003] [Indexed: 11/26/2022] Open
Abstract
Over the last 6 years, 161 patients underwent implantation of HeartMate single-lead vented electric (SLVE) devices as a bridge to transplantation. SLVE patients were retrospectively analyzed before and after United Network for Organ Sharing (UNOS) policy changes, and designated SLVE-1 and SLVE-2, respectively. Mean support time decreased significantly from 79.7 +/- 72.0 days to 55.3 +/- 60.5 days (p = 0.022). Although not statistically significant, rate of successful bridging to transplant increased from 70.3% to 74.7%, and post-transplant 1- and 3-year survival increased from 90.0% and 86.0%, respectively, to 92.9% and 87.3%, respectively.
Collapse
Affiliation(s)
- Jeffrey A Morgan
- Department of Surgery, Division of Cardiothoracic Surgery, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
| | | | | | | | | |
Collapse
|
15
|
Nabavi DG, Stockmann J, Schmid C, Schneider M, Hammel D, Scheld HH, Ringelstein EB. Doppler microembolic load predicts risk of thromboembolic complications in Novacor patients. J Thorac Cardiovasc Surg 2003; 126:160-7. [PMID: 12878951 DOI: 10.1016/s0022-5223(03)00019-9] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Left ventricular assist devices have become an established method to bridge patients with end-stage cardiac failure to heart transplantation. Besides infection and bleeding, thromboembolism represents one of the most serious complications. We evaluated the value of microembolic signals in predicting thromboembolic events for individual patients and distinctive left ventricular assist device periods. METHODS Twenty patients (14 male) aged 23-57 years supported with the Novacor N100 left ventricular assist device were enrolled in this study. All patients were on effective anticoagulation, 12 patients additionally received antiplatelet therapy. Unilateral detection of microembolic signals was performed once weekly by insonation of the middle cerebral artery using transcranial Doppler sonography for 30 minutes duration. Evidence of clinically manifest thromboembolic events was based on regular questionnaires, clinical examinations, and results of diagnostic procedures. RESULTS During a cumulative follow-up of 3876 left ventricular assist device days, 44 thromboembolic complications occurred (incidence, 1.1%) in 15 out of 20 patients. A total of 360 transcranial Doppler sonography monitorings (range, 5-34 per patient) were performed with an overall microembolic signals prevalence of 35.3% and a microembolic signal mean of 2.3 +/- 9.2 per examination. There was a highly significant correlation between the individual microembolic signal activity and the respective incidence of clinical thromboembolism (r = 0.61-0.9; P <.01). Patients with additional antiplatelet treatment had significantly less thromboembolic complications (0.7%) and lower microembolic signal prevalence (18.3%) than those without (2.8% and 65.4%, respectively). Individual patients and left ventricular assist device months with clinical thromboembolization could be identified using the microembolic signal activity with moderate positive (0.37-0.7) and high negative predictive values (0.82-1.0). CONCLUSIONS The amount of microembolic signals, serially detected in patients with the Novacor left ventricular assist device, is significantly associated with their incidence of embolic complications. The high negative predictive value of microembolic signals enables to identify those patients and left ventricular assist device periods with particularly low risk of clinical thromboembolization.
Collapse
|
16
|
Savage L. Quality of life among patients with a left ventricular assist device: what is new? AACN CLINICAL ISSUES 2003; 14:64-72. [PMID: 12574704 DOI: 10.1097/00044067-200302000-00008] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
As more patients have a diagnosis of end-stage heart failure, nurses are more likely to encounter the use of left ventricular assist devices (LVADs). Currently, LVADs are used as a bridge to cardiac transplantation. However, current research suggests that LVADs may be used as destination therapy for those unable to undergo cardiac transplantation. The technology has been developed to sustain life, but what is the impact of technology on the quality of life? This article reviews current research on the quality of life with an LVAD.
Collapse
Affiliation(s)
- Laura Savage
- Virginia Commonwealth University Health System, Medical College of Virginia Hospitals and Physicians, Richmond, USA.
| |
Collapse
|
17
|
Jaski BE, Kim JC, Naftel DC, Jarcho J, Costanzo MR, Eisen HJ, Kirklin JK, Bourge RC. Cardiac transplant outcome of patients supported on left ventricular assist device vs. intravenous inotropic therapy. J Heart Lung Transplant 2001; 20:449-56. [PMID: 11295583 DOI: 10.1016/s1053-2498(00)00246-1] [Citation(s) in RCA: 77] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Although the left ventricular assist device (LVAD) has been increasingly used as a bridge to transplant, its effect on post-transplant outcome is uncertain. We, therefore, designed this study using the Cardiac Transplant Research Database to compare patients supported on an LVAD before transplant with those treated with intravenous inotropic medical therapy. METHODS AND RESULTS Of the 5,880 patients transplanted between 1990 and 1997, a total of 502 received support from LVADs and 2,514 received intravenous inotropic medical therapy at the time of transplant. Kaplan-Meier analysis showed no significant difference in post-transplant survival between the LVAD and medical-therapy groups (p = 0.09). Results of a multivariate Cox regression analysis were consistent with that of the Kaplan-Meier analysis and did not identify LVAD as a significant risk factor for mortality. The percentage of patients who received LVADs as a function of total transplants increased from 2% in 1990 to 16% in 1997. Furthermore, although the number of extracorporeal LVADs remained relatively constant, the number of intracorporeal LVADs increased over time. Multivariate parametric analysis found that the risk factors for post-transplant death in the LVAD group were extracorporeal LVAD use (p = 0.0004), elevated serum creatinine (p = 0.05), older donor age (p = 0.03), increased donor ischemic time (p < 0.0001), and earlier year of transplant (p = 0.03). CONCLUSIONS Given a limited donor supply, the intracorporeal LVAD helps the sickest patients survive to transplant and provides post-transplant outcome similar to that of patients supported on inotropic medical therapy. Therefore, patients supported on LVADs before transplant may receive the greatest marginal benefit when compared with other transplant candidates.
Collapse
Affiliation(s)
- B E Jaski
- University of Alabama, Birmingham, Alabama, USA
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Abstract
Right heart failure continues to affect our clinical success with left ventricular assist device support. The inability to consistently predict the probability of the onset of right heart dysfunction contributes to this problem. We have developed an aggressive approach to the management of these patients in an attempt to decrease the incidence of this condition, which continues to carry a very high operative mortality.
Collapse
Affiliation(s)
- C H Van Meter
- Division of Cardiothoracic Surgery and Transplantation, Alton Ochsner Medical Foundation, New Orleans, Louisiana, USA
| |
Collapse
|
19
|
Mahmood AK, Courtney JM, Akdis M, Reul H, Westaby S. Critical review of current left ventricular assist devices. Perfusion 2000; 15:399-420. [PMID: 11001163 DOI: 10.1177/026765910001500502] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- A K Mahmood
- Bioengineering Unit, University of Strathclyde, Glasgow.
| | | | | | | | | |
Collapse
|
20
|
McCarthy PM, Smedira NG. Implantable LVAD insertion in patients with previous heart surgery. J Heart Lung Transplant 2000; 19:S95-100. [PMID: 11016496 DOI: 10.1016/s1053-2498(99)00103-5] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Implantable LVAD insertion and support poses technical obstacles in patients with previous heart operations. In this study of 135 LVAD patients (64 pneumatic HeartMate; 39 vented-electric HeartMate; 32 Novacor devices), 72 (53%) had previous heart surgery. For patients with previous coronary artery bypass, the grafts were managed by replacement or preservation. For patients with ventricular aneursym (or aneursmysectomy), or partical left ventriculectomy, apical cannulation had to be modified to maintain precise unobstructed orientation of the inflow cannula towards the mitral valve. Mechanical mitral and aortic prostheses were rereplaced with tissue valves. Implantable cardioverter defibrillators were removed, or the LVAD pump was placed intraperitoneal and the generator was left in the abdominal wall pocket. There were no significant differences in reoperations for bleeding (22% primary vs 23% reoperations), perioperative RVAD support (12% primary vs 7% reoperation) or survival to transplant (82% primary vs 72% reoperations). In conclusion adjustment of standard LVAD implant technique can successfully manage most problems posed by patients with previous heart surgery.
Collapse
Affiliation(s)
- P M McCarthy
- Department of Thoracic and Cardiovascular Surgery, Kaufman Center for Heart Failure, Cleveland Clinic Foundation, Ohio 44195, USA.
| | | |
Collapse
|
21
|
Scalia GM, McCarthy PM, Savage RM, Smedira NG, Thomas JD. Clinical utility of echocardiography in the management of implantable ventricular assist devices. J Am Soc Echocardiogr 2000; 13:754-63. [PMID: 10936819 DOI: 10.1067/mje.2000.105009] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
BACKGROUND The high mortality rate of congestive cardiac failure, the cost and complications of cardiac transplantation, and the waiting list mortality rate resulting from donor organ scarcity have encouraged the development of surgical techniques as bridges to transplantation or as long-term palliative therapy. Implantable left ventricular assist devices are now routinely used as such a bridge, and within the REMATCH Trial, as permanent palliative devices in nontransplant candidates. These are mechanical managements with myriad mechanical complications and pitfalls. Echocardiography has been extensively used in our institution to detect and diagnose previously documented and hitherto unencountered complications of these procedures. METHODS AND RESULTS The role of echocardiography in these procedures, including preoperative patient selection, intraoperative transesophageal echocardiography, and postoperative troubleshooting and late follow-up, is discussed. We describe our clinical echocardiographic approach, which has developed over 91 assist-device procedures. The relative frequency and clinical impact of specific anatomic, physiologic, hemodynamic, and mechanical features are described. New techniques such as the Doppler quantification of assist device inflow obstruction are illustrated, as are the device cannula position, the detection of device valve failure, and the parameters related to the remodeling procedure. CONCLUSIONS Echocardiography in heart failure surgery has proved to be an invaluable tool in the diagnosis and management of mechanical complications. The experience gained in our institution may serve as an aid to new surgical programs treating these critically ill patients.
Collapse
Affiliation(s)
- G M Scalia
- Cardiovascular Imaging Center and the Departments of Cardiothoracic Surgery and Cardiothoracic Anesthesia, The Cleveland Clinic Foundation,Ohio 44195, USA
| | | | | | | | | |
Collapse
|
22
|
Lewis ME, Pitt MP, Bonser RS. Surgical alternatives to mechanical support. Perfusion 2000; 15:379-86. [PMID: 10926424 DOI: 10.1177/026765910001500416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- M E Lewis
- Department of Cardiothoracic Surgery, Queen Elizabeth Hospital, Edgbaston, Birmingham
| | | | | |
Collapse
|
23
|
Minami K, El-Banayosy A, Sezai A, Arusoglu L, Sarnowsky P, Fey O, Koerfer R. Morbidity and outcome after mechanical ventricular support using Thoratec, Novacor, and HeartMate for bridging to heart transplantation. Artif Organs 2000; 24:421-6. [PMID: 10886058 DOI: 10.1046/j.1525-1594.2000.06621.x] [Citation(s) in RCA: 77] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Between September 1989 and June 1999, 228 patients were supported with a ventricular assist device as a bridge to heart transplantation. In this study, the results of implantation were evaluated in patients supported with one type of device, including 85 supported with a Thoratec, 61 with a Novacor, and 37 with a HeartMate. The mean support time was 49, 148, and 124 days, respectively. Successful transplantation and weaning rates were 64. 7% with Thoratec, 59.0% with Novacor, and 62.0% with HeartMate. Cerebral embolism and drive-line and pocket infection were major causes of postoperative morbidity and mortality. We recommended that a Thoratec system be employed as a bridge to heart transplantation for patients with biventricular heart failure, and that a Novacor or HeartMate system be implanted in patients requiring a long-term circulatory support.
Collapse
Affiliation(s)
- K Minami
- Department of Thoracic and Cardiovascular Surgery, Heart Center North-Rhine-Westphalia Bad Oeynhausen, Ruhr-University, Bochum, Germany
| | | | | | | | | | | | | |
Collapse
|
24
|
Park SJ, Nguyen DQ, Bank AJ, Ormaza S, Bolman RM. Left ventricular assist device bridge therapy for acute myocardial infarction. Ann Thorac Surg 2000; 69:1146-51. [PMID: 10800809 DOI: 10.1016/s0003-4975(99)01575-1] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Patients with acute myocardial infarction (AMI) complicated by cardiogenic shock have a high mortality rate. Current treatment modalities remain suboptimal for these patients. METHODS From April 1995 to March 1998, 7 patients were identified as having AMI associated with cardiogenic shock. All received intraaortic balloon pump assistance, in addition to maximal inotropic support. RESULTS The mean preoperative cardiac index was 2.0+/-0.3 L/min/m2 and pulmonary capillary wedge pressure was 23+/-6 mm Hg. Three patients received thrombolytic therapy and 4 patients underwent percutaneous transluminal coronary angioplasty without success. Left ventricular assist devices (LVADs) were implanted as bridge therapy to heart transplantation. One patient died from recurrence of a ventricular septal defect during LVAD support. Six patients were transplanted successfully after mean LVAD support of 59+/-33 days. Five patients are alive and well at a mean follow-up of 898+/-447 days. One patient died 3 days after transplantation from acute allograft dysfunction. CONCLUSIONS Timely application of LVADs as bridge therapy to heart transplantation in these critically ill patients can be lifesaving, and should be investigated further.
Collapse
Affiliation(s)
- S J Park
- Division of Cardiovascular and Thoracic Surgery, University of Minnesota Hospital and Clinic, Minneapolis, USA.
| | | | | | | | | |
Collapse
|
25
|
Jaski BE, Lingle RJ, Kim J, Branch KR, Goldsmith R, Johnson MR, Lahpor JR, Icenogle TB, Piña I, Adamson R, Favrot LK, Dembitsky WP. Comparison of functional capacity in patients with end-stage heart failure following implantation of a left ventricular assist device versus heart transplantation: results of the experience with left ventricular assist device with exercise trial. J Heart Lung Transplant 1999; 18:1031-40. [PMID: 10598726 DOI: 10.1016/s1053-2498(99)00071-6] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Use of a permanent left ventricular assist device (LVAD) has been proposed as an alternate treatment of patients with end-stage heart failure. The purpose of this study was to compare the functional capacity of patients following implantation of a LVAD vs heart transplant (HTx). METHODS Eighteen patients from 6 centers who received an intracorporeal LVAD as a bridge to HTx underwent treadmill testing 1 to 3 months post-LVAD and again post-HTx. Baseline and peak measurements, including oxygen consumption, blood pressures, and respiratory rate were made during each treadmill test. RESULTS Peak oxygen consumption was 14.5+/-3.9 ml/kg/minute post-LVAD and 17.5+/-5.0 ml/kg/minute post-HTx (p < .005). The percentage of the predicted peak oxygen consumption based on gender, weight, and age was 39.5%+/-5.5% post-LVAD and 47.7%+/-10.9% post-HTx (p < .005). Exercise duration was lower post-LVAD than post-HTx (10.3+/-4.2 minute vs 12.5+/-5.4 minute, p < .05). After LVAD implantation, peak total oxygen consumption correlated with peak LVAD rate and output. Eight patients reached an LVAD rate of 120 beats per minute (bpm) before the conclusion of exercise, the maximum rate for the outpatient electric device. The peak respiratory exchange ratio post-LVAD was 1.15+/-0.22 and post-HTx was 1.15+/-0.18, consistent with a good effort in both groups. CONCLUSIONS Patients demonstrated a lower functional capacity post-LVAD than post-HTx. For some patients functional capacity post-LVAD may be improved by a higher maximum LVAD rate and output.
Collapse
Affiliation(s)
- B E Jaski
- San Diego Cardiac Center, CA 92123, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Nishimura M, Ohtake S, Sawa Y, Fukushima N, Yamaguchi T, Matsuda H. Left ventricular assist systems as a bridge to heart transplantation: the role and the strategy in Japan. Transplant Proc 1999; 31:1997-9. [PMID: 10455949 DOI: 10.1016/s0041-1345(99)00242-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- M Nishimura
- First Department of Surgery, Osaka University Medical School, Japan
| | | | | | | | | | | |
Collapse
|
27
|
Yoshikawa M, Nakata K, Ohtsuka G, Takano T, Glueck J, Fujisawa A, Makinouchi K, Yokokawa M, Nosé Y. Feasibility of a tiny Gyro centrifugal pump as an implantable ventricular assist device. Artif Organs 1999; 23:774-9. [PMID: 10463506 DOI: 10.1046/j.1525-1594.1999.06421.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The Gyro pumps were developed for long-term circulatory support. The first generation Gyro pump (C1E3) achieved 1 month paracorporeal circulatory support in chronic animal experiments; the second generation (PI702) implantable ventricular assist device (VAD) was successful for over 6 months. The objective of the next generation Gyro pump is for use as a long-term totally implantable VAD and for pediatric circulatory support. This tiny Gyro pump (KP101) was fabricated with the same design concept as the other Gyro pumps. The possibility of an implantable VAD was determined after performance and hemolysis test results were compared to those of the other Gyro pumps. The pump housing and impeller were fabricated from polycarbonate with an impeller diameter of 35 mm. The diameter and height of the pump housings are 52.3 mm and 29.9 mm, respectively. At this time, a DC brushless motor drives the KP101, which is the same as that for the C1E3. The pump performance was measured in 37% glycerin water at 37 degrees C. Hemolysis tests were performed utilizing a compact mock loop filled with fresh bovine blood in a left ventricular assist device (LVAD) condition at 37 degrees C. The KP101 achieved the LVAD conditions of 5 L/min and 100 mm Hg at 2,900 rpm; generated 10 L/min against 100 mm Hg at 3,200 rpm; 3 L/min against 90 mm Hg at 2,600 rpm; and 2 L/min against 80 mm Hg at 2,400 rpm. In addition, the pump efficiency during this experiment was 12.5%. The other Gyro pumps. that is, the C1E3, PI601, and PI701, in an LVAD condition require 1,600, 2,000, and 2,000 rpm, respectively. The KP101 produced a normalized index of hemolysis (NIH) value of 0.005 g/100 L. With regard to the NIH, the other Gyro pumps, namely the C1E3, PI601, and PI701 demonstrated 0.0007, 0.0028, and 0.004 g/100 L, respectively. The KP101 produced an acceptable pressure flow curve for a VAD. The NIH value was higher than that of other Gyro pumps, but is in an acceptable range.
Collapse
Affiliation(s)
- M Yoshikawa
- Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Knight JL. Mechanical circulatory support devices in the treatment of heart failure. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE 1999; 29:410-7. [PMID: 10868513 DOI: 10.1111/j.1445-5994.1999.tb00736.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
With an increasingly aging population, heart failure is a major health issue, affecting more than 10% of the population over 65 years of age, and costing hundreds of millions of dollars per year for ongoing care. Even with maximal medical therapy, annual mortality rates of in excess of 25% are commonly reported. Over the last three decades, various surgical approaches have been examined in the hope of improving the outcome of congestive cardiac failure. These procedures range from simple coronary revascularisation to left ventricular reduction surgery and cardiac transplantation. Although of value in selected situations, no surgical approach, beyond transplantation, has had significant impact on the outcome of heart failure. In the last decade, development in the area of mechanical support for the failing heart has continued to expand at a rapid rate. Strong evidence now exists to show that in many patients with advanced heart failure, prolonged mechanical support results in significant myocardial recovery. There are currently several mechanical support devices available for clinical use, although most are considered experimental in this country. These devices are expensive and are not without significant complications, but early results of their use as either a bridge to transplantation or as a stand alone treatment, have been very encouraging. Currently available mechanical assist devices are described, with discussion of indications for implantation, complications and results of their use.
Collapse
Affiliation(s)
- J L Knight
- Cardiac Surgery, Flinders Medical Centre, Adelaide, SA
| |
Collapse
|
29
|
Mussivand T, Hendry PJ, Masters RG, Keon WJ. Development of a ventricular assist device for out-of-hospital use. J Heart Lung Transplant 1999; 18:166-71. [PMID: 10194041 DOI: 10.1016/s1053-2498(98)00008-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND Success with temporary ventricular assist devices, has prompted interest in devices developed for long term use outside of the hospital setting. METHODS A totally implantable intrathoracic electro-hydraulic ventricular assist device has been developed. Design focused on providing the recipient with a near normal quality of life. To meet this goal the system utilizes transcutaneous energy transfer and biotelemetry to eliminate percutaneous drive-lines/cables as well as a displacement chamber capable of pressure equalization to atmospheric pressures, so as to eliminate the need for percutaneous venting. An implanted battery provides backup power to allow the recipient the ability to bathe, shower, or swim without connection to an external power source. An integrated telemedicine capability allows the device to be monitored/controlled remotely, using telephone lines. RESULTS The system has been tested in vitro with early prototypes running for up to 5 1/2 years. The system was studied in calves (n = 25) with durations of support of up to 30 days, demonstrating the ability of the device to function as a totally implantable device without percutaneous connections. CONCLUSIONS The various in vitro and in vivo studies have demonstrated the feasibility of the totally implantable device. Chronic in vivo experiments will follow in preparation for regulatory submissions for human use.
Collapse
Affiliation(s)
- T Mussivand
- Cardiovascular Devices Division, University of Ottawa Heart Institute, Ontario, Canada
| | | | | | | |
Collapse
|
30
|
Abstract
As the next millennium approaches, excitement and promise characterize the future of dilated cardiomyopathy. Until recently, dilated cardiomyopathy was considered an incurable, uniformly fatal chronic disease. Epidemiologic studies have demonstrated that at least a quarter of patients with recent onset of symptoms with cardiomyopathy manifest spontaneous improvement and a sustained favorable prognosis. It is imperative that patients who present with new-onset cardiomyopathy be managed medically and closely followed. Medical treatment remains the foundation of therapy, and certainly the advent of beta-blocker use may herald further benefit beyond that observed with conventional therapy (ACE inhibitors and digoxin). Unless mechanical support is required for hemodynamic instability and end organ failure, patients should be treated medically and observed. As discussed earlier, transient mechanical support as a bridge to recovery should be considered in the appropriate clinical scenario before committing to cardiac transplantation. Patients with established disease who have been followed for extended periods (> 6 months) that have progressive symptoms despite optimal medical therapy should be considered for surgical therapies. Cardiac transplantation is available to only a minority of the diseased population. All newer modalities of surgical unloading therapy theoretically reduce wall stress. Clearly in dilated cardiomyopathy, ventricular performance is reduced; however, individual myocyte contractile function may be intact. Studies of isolated myocytes (which are unloaded) have yielded conflicting data; however, if contractile function is intact and performance is reduced primarily secondary to abnormal loading conditions, surgical unloading therapies should yield benefit. Hence the thesis of Batista that geometric alteration will improve performance assumes intrinsic integrity of the myocyte contractile function. The implication of intrinsic myocyte contractile dysfunction is that surgical remodeling does not yield improved ventricular performance. Although clinicians have learned that selection criteria appear to play a role in predicting beneficial outcomes with cardiomyoplasty and the Batista procedure, clinical techniques to assess the integrity of myocyte function are unsophisticated. Quantifying interstitial fibrosis, assays for the degree of apoptosis, and various immunologic measures currently do not provide the insight necessary to predict outcomes reliably. The future assessment of dilated cardiomyopathy and the decision to consider alternative surgical procedures versus cardiac transplantation will likely be determined by biomolecular studies. At present, these new surgical procedures are promising therapies and potential alternatives to cardiac transplantation. Controlled studies to determine the clinical and survival benefit compared with medical therapy will ultimately be required, after the surgical techniques and patient selection criteria are refined. Randomized, prospective controlled studies assessing LVAD therapy and cardiomyoplasty are in progress.
Collapse
Affiliation(s)
- R C Starling
- Section of Heart Failure and Cardiac Transplant Medicine, George M. and Linda H. Kaufman Center for Heart Failure, Cleveland Clinic Foundation, Ohio, USA.
| | | |
Collapse
|
31
|
Takami Y, Otsuka G, Mueller J, Sugita Y, Nakata K, Tayama E, Ohashi Y, Schima H, Schmallegger H, Wolner E, Nosé Y. In vivo evaluation of the miniaturized Gyro centrifugal pump as an implantable ventricular assist device. Artif Organs 1998; 22:713-20. [PMID: 9702327 DOI: 10.1046/j.1525-1594.1998.06021.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
A miniaturized Gyro centrifugal pump has been developed to be incorporated into a totally implantable artificial heart. The Gyro PI (permanently implantable) model is a pivot bearing supported centrifugal pump with a priming volume of 20 ml. With the miniaturized actuator, the pump-actuator package has a height of 53 mm, a diameter of 65 mm, and a displacement volume of 145 ml. To evaluate the hemocompatibility and efficiency of the Gyro PI pump system, a plastic prototype (Gyro PI-601) was implanted into a bovine model as a left or right ventricular assist device (LVAD or RVAD), bypassing from the left ventricular apex to the descending aorta or from the right ventricular infundibulum to the main pulmonary artery. The calves were anticoagulated with heparin to maintain activated clotting times from 150 to 200 s. Four calves were supported for 23, 24, and 50 days in the LVAD studies, and 40 days in the RVAD study. The first calf died due to intrathoracic bleeding associated with sepsis. The second calf was euthanized for a low flow rate less than 2 L/min due to an obstructed inflow with growing pannus. The third and fourth calves were euthanized as scheduled. Renal and hepatic functions remained normal, and plasma free hemoglobin values were less than 8 mg/dL throughout the experiments. The fourth case showed flow rates of 4.83 +/- 0.57 L/min, input power of 6.16 +/- 0.49 W, and the inside temperature of the actuator of 43.5 +/- 0.52 degrees C. The pumps implanted in the fourth calf demonstrated no thrombus formation at the autopsy. These in vivo experiments revealed that the Gyro PI pump can provide adequate flow as an easily implantable, efficient, antithrombogenic, and nonhemolytic centrifugal LVAD or RVAD with miniaturized actuators.
Collapse
Affiliation(s)
- Y Takami
- Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Chesler NC, Kamm RD. Performance analysis of a cardiac assist device in counterpulsation. J Biomech Eng 1998; 120:437-45. [PMID: 10412413 DOI: 10.1115/1.2798012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Performance of a cardiac assist device pumping chamber in counterpulsation was evaluated using numerical simulations of the unsteady, three-dimensional flow inside the chamber and an analytical model of the force required to eject and fill the chamber. The wall shear stress within the device was similarly computed and modeled. The analytical model was scaled to match the numerical results and then used to predict performance at physiological operating conditions. According to these models for a stroke volume of 70 ml, between 0.4 and 1.0 W is required for counterpulsation at a frequency of 1.33 Hz against a restorative spring, depending on the spring constant chosen. The power and the maximum force calculated are within the ranges a trained skeletal muscle is capable of providing. Shear stress predictions show that platelet activation in the absence of surface effects and hemolysis due to high shear are unlikely to occur with this design. Furthermore, vortices that develop in the chamber during filling are predicted to increase blood mixing and provide favorable washing of the chamber walls. A computational-analytical approach such as this may have potential to aid rapid performance evaluation of new devices and streamline the design optimization process.
Collapse
Affiliation(s)
- N C Chesler
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge 02139, USA
| | | |
Collapse
|
33
|
Uretsky BF, Pina I, Quigg RJ, Brill JV, MacInerney EJ, Mintzer R, Armstrong PW. Beyond drug therapy: nonpharmacologic care of the patient with advanced heart failure. Am Heart J 1998; 135:S264-84. [PMID: 9630090 DOI: 10.1016/s0002-8703(98)70255-8] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- B F Uretsky
- Division of Cardiology, University of Texas Medical Branch at Galveston, USA
| | | | | | | | | | | | | |
Collapse
|
34
|
McCarthy PM, Smedira NO, Vargo RL, Goormastic M, Hobbs RE, Starling RC, Young JB. One hundred patients with the HeartMate left ventricular assist device: evolving concepts and technology. J Thorac Cardiovasc Surg 1998; 115:904-12. [PMID: 9576228 DOI: 10.1016/s0022-5223(98)70373-3] [Citation(s) in RCA: 209] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND Implantable left ventricular assist devices are common as a bridge to transplantation but are just reaching their goal as an alternative to transplantation. METHODS From December 1991 until December 1996, 97 left ventricular assist devices were implanted as a bridge to transplantation, one as an alternative to transplantation, and two as a bridge to recovery. Included were 64 pneumatic devices and 36 electric devices. Most patients (69%) had ischemic cardiomyopathy and most (53%) had had previous cardiac surgery. Preoperative circulatory support (extracorporeal membrane oxygenation) was used in 25. RESULTS Perioperative insertion of a right ventricular assist device was unusual (11%). The mean duration of support with a left ventricular assist device (bridge to transplantation) was 70 +/- 41 days (up to 206 days). Survival to transplantation was 76%. Cause of death included multiple organ failure (n = 13), perioperative stroke (n = 5), device failure (n = 5), and controller disconnect (n = 1). Significant risk factors for death included (1) preoperative need for ventilator or extracorporeal membrane oxygenation, (2) elevated blood urea nitrogen, creatinine, or bilirubin, and (3) low pulmonary artery pressures. Risks after insertion of the left ventricular assist device were reoperation for bleeding, support with a right ventricular assist device, dialysis, or device failure. Catastrophic failure of the device occurred 14 times in 12 patients and was treated by emergency pump exchange in six instances. Only two device-related thromboembolic episodes were detected. Positive blood cultures were found in 59% of patients, driveline infection in 28%, and pump infection in 11%. CONCLUSIONS The HeartMate device provided excellent hemodynamic support with low device-related thromboembolic events. Infection and reliability of the device contributed to the high cost of therapy. These areas need to be improved for the left ventricular assist device to attain its goal as a viable alternative to transplantation.
Collapse
Affiliation(s)
- P M McCarthy
- Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Ohio 44195, USA
| | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
The need for mechanical circulatory support after car diac surgery is uncommon despite an older and increas ingly sicker patient population. From September 1992 through January 1997, surgeons performed 21,000 car diac operations at the Cleveland Clinic Foundation, and mechanical support postcardiotomy was required in only 75 patients (0.3%). Aggressive management of cardiac and pulmonary dysfunction usually results in successful weaning from cardiopulmonary bypass. How ever, when mechanical support is needed, it can tax the resources of the institution and requires integrated patient management from the entire health care team. Management of postcardiotomy circulatory failure will be discussed in detail, along with the devices commer cially available for both short- and long-term support. Copyrighr© 1998 by W. B. Saunders Company.
Collapse
Affiliation(s)
- Nicholas G. Smedira
- Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, OH
| | - Christopher C. Hlozek
- Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, OH
| | - Patrick M. McCarthy
- Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, OH
| |
Collapse
|
36
|
DeRose JJ, Umana JP, Argenziano M, Catanese KA, Gardocki MT, Flannery M, Levin HR, Sun BC, Rose EA, Oz MC. Implantable left ventricular assist devices provide an excellent outpatient bridge to transplantation and recovery. J Am Coll Cardiol 1997; 30:1773-7. [PMID: 9385906 DOI: 10.1016/s0735-1097(97)00396-3] [Citation(s) in RCA: 92] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
OBJECTIVES Our recent experience with outpatient left ventricular assist device (LVAD) support is presented to demonstrate the possibilities and limitations of long-term outpatient mechanical circulatory assistance. BACKGROUND The experience with inpatient LVAD support as a bridge to transplantation has proved the efficacy of such therapy in improving circulatory hemodynamic status, restoring normal end-organ function and facilitating patient rehabilitation. With miniaturization of the power supplies and controllers, such mechanical circulatory support can now be accomplished in an outpatient setting. METHODS Between March 1993 and February 1997, 32 patients (26 male, 6 female, mean [+/-SEM] age 49 +/- 15 years) underwent implantation of the ThermoCardiosystems (TCI) Heartmate vented electric (VE) LVAD. The VE LVAD is powered by batteries worn on shoulder holsters and is operated by a belt-mounted system controller, allowing unrestricted patient ambulation and hospital discharge. RESULTS Mean duration of support was 122 +/- 26 days (range 3 to 605), with a survival rate to transplantation or explantation of 78%. Nineteen patients were discharged from the hospital on mean postoperative day 41 +/- 4 (range 17 to 68), for an outpatient support time of 108 +/- 30 days (range 2 to 466). Four patients underwent early transplantation and could not participate in the discharge program, and three patients currently await discharge. The complication rate was not statistically different from that encountered in our previous 52 patients with a pneumatic LVAD. CONCLUSIONS Outpatient LVAD support is safe and provides improved quality of life for patients awaiting transplantation. Wearable and totally implantable LVADs should be studied as permanent treatment options for patients who are not candidates for heart transplantation.
Collapse
Affiliation(s)
- J J DeRose
- Division of Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
Despite the advances in the medical management of heart failure over the last 20 years it remains a major cause of morbidity and mortality. While cardiac transplantation has evolved into an established mode of therapy, the number of patients with severe heart failure who could benefit from cardiac transplantation far exceeds the supply of donor organs. The development of an implantable left ventricular assist device (LVAD) began in the early 1970s in centres such as the Texas Heart Institute and was funded by the National Heart, Lung, and Blood Institute. Clinical trials of these devices began in the mid 1980s and several hundred patients have now been supported with one or other of these devices. Most patients have had an LVAD implanted as a bridge to cardiac transplantation. Recently there has also been interest in the use of an LVAD for (a) permanent ventricular support and (b) as a bridge to recovery in patients with potentially reversible causes of heart failure.
Collapse
Affiliation(s)
- J Parameshwar
- Transplant Unit, Papworth Hospital, Papworth Everard, Cambridge, UK
| | | |
Collapse
|
38
|
Westaby S, Jin XY, Katsumata T, Taggart DP, Coats AJ, Frazier OH. Mechanical support in dilated cardiomyopathy: signs of early left ventricular recovery. Ann Thorac Surg 1997; 64:1303-8. [PMID: 9386694 DOI: 10.1016/s0003-4975(97)00910-7] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND Recent reports have documented left ventricular recovery in patients with dilated cardiomyopathy off-loaded long term with a left ventricular assist device. We sought to document the natural history of left ventricular recovery. METHODS We implanted the TCI left ventricular assist device without the intention to perform transplantation in 2 patients with dilated cardiomyopathy who had been rejected for transplantation. Both were in New York Heart Association functional class IV and had renal failure. One was a diabetic. We studied left ventricular function with detailed echocardiography at 4, 6, and 8 weeks postoperatively. RESULTS With the left ventricular assist device turned off, we observed a progressive increase in myocardial contractility beginning as early as 4 weeks after implantation and improving progressively. Histologic examination showed resolution of myocytolysis in both patients. CONCLUSIONS Left ventricular recovery begins earlier than was previously suspected. Mechanical bridge to myocardial recovery is a potential approach to therapy for such patients.
Collapse
Affiliation(s)
- S Westaby
- Department of Cardiac Surgery, Oxford Heart Centre, John Radcliffe Hospital, England
| | | | | | | | | | | |
Collapse
|
39
|
DeRose JJ, Argenziano M, Sun BC, Reemtsma K, Oz MC, Rose EA. Implantable left ventricular assist devices: an evolving long-term cardiac replacement therapy. Ann Surg 1997; 226:461-8; discussion 468-70. [PMID: 9351714 PMCID: PMC1191061 DOI: 10.1097/00000658-199710000-00007] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
OBJECTIVE The authors' 8-year experience with both inpatient and outpatient left ventricular assist device (LVAD) support is presented to show the possibilities and limitations of long-term outpatient mechanical circulatory assistance. SUMMARY BACKGROUND DATA The limitation of suitable cardiac donors has led to the use of LVADs as a temporizing measure for patients awaiting cardiac transplantation. The success of such devices in the short and medium term as a bridge to transplantation has led to their evaluation as a long-term destination therapy for end-stage heart disease. METHODS Between August 1990 and February 1997, 85 patients with end-stage heart disease underwent insertion of implantable LVADs. Fifty-two patients underwent pneumatic device insertion and 32 patients received a vented electric device. RESULTS Patients were supported for a mean of 109+/-13 days for an overall survival to transplant (54) or explant (3) of 73%. Nineteen patients were discharged from the hospital on a mean of postoperative day 41+/-4 (range, 17-68) for an outpatient support time of 108+/-30 days (range, 2-466). Of 12 patients supported after postcardiotomy cardiogenic shock, 10 (82%) survived to hospital discharge. Perioperative right ventricular failure was treated in most patients with inotropic agents and inhaled nitric oxide with only six patients requiring right ventricular assist device support. Thromboembolic rate was low (0.016 events/patient-month) despite minimal or no anticoagulation in all cases. CONCLUSIONS Left ventricular assist device support has evolved to become an outpatient therapy with excellent survival rates and an acceptable morbidity. Accordingly, wearable LVADs should be studied as permanent treatment options for patients who are not transplant candidates.
Collapse
Affiliation(s)
- J J DeRose
- Division of Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | | | | | | | | | | |
Collapse
|
40
|
Takami Y, Nakazawa T, Otsuka G, Tayama E, Ohashi Y, Sueoka A, Schima H, Schmallegger H, Wolner E, Nosé Y. Anatomical consideration for an implantable centrifugal biventricular assist system. Artif Organs 1997; 21:1132-6. [PMID: 9335374 DOI: 10.1111/j.1525-1594.1997.tb00455.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
A miniaturized pivot bearing-supported centrifugal blood pump (Gyro PI) has been developed as a long-term biventricular assist system (BiVAS). In this study we determined the anatomical configuration of this system using a bovine model. Under general anesthesia, a left lateral thoracotomy was performed to open the chest. Two Gyro PI-601 pumps for left and right assists were placed in the preperitoneal pocket by a subcostal abdominal incision. The left pump could be placed along the dome of the diaphragm just beneath the apex of the left ventricle. The right pump could be placed next to the left pump. The inlet and outlet ports of both pumps penetrated the diaphragm. The inlet port of the left pump, with a length of 55 mm, was inserted directly into the apex of the left ventricle. A woven Dacron graft (150 mm long, 11 mm inner diameter) was placed between the outlet port of the left pump and the descending aorta. As for the right pump, a 100 mm long and 120 degree angled inflow conduit was placed between the inlet port and the right ventricular infundibulum. The outlet port of the right pump was connected to the main trunk of the pulmonary artery using a 90 mm long, 11 mm inner diameter Dacron graft. We could perform biventricular assistance to confirm the anatomical feasibility of the Gyro implantable centrifugal BiVAS.
Collapse
Affiliation(s)
- Y Takami
- Department of Surgery, Baylor College of Medicine, Houston, Texas, U.S.A
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Montiès JR, Dion I, Havlik P, Rouais F, Trinkl J, Baquey C. Cora rotary pump for implantable left ventricular assist device: biomaterial aspects. Artif Organs 1997; 21:730-4. [PMID: 9212947 DOI: 10.1111/j.1525-1594.1997.tb03731.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Our group is developing a left ventricular assist device based on the principle of the Maillard-Wankel rotative compressor: it is a rotary, not centrifugal, pump that produces a pulsatile flow. Stringent requirements have been defined for construction materials. They must be light, yet sufficiently hard and rigid, and able to be machined with high precision. The friction coefficient must be low and the wear resistance high. The materials must be chemically inert and not deformable. Also, the materials must be biocompatible, and the blood contacting surface must be hemocompatible. We assessed the materials in terms of physiochemistry, mechanics, and tribology to select the best for hemocompatibility (determined by studies of protein adsorption; platelet, leukocyte, and red cell retention; and hemolysis, among other measurements) and biocompatibility (determined by measurement of complement activation and toxicity, among other criteria). Of the materials tested, for short- and middle-term assistance, we chose titanium alloy (Ti6Al4V) and alumina ceramic (Al2O3) and for long-term and permanent use, composite materials (TiN coating on graphite). We saw that the polishing process of the substrate must be improved. For the future, the best coating material would be diamond-like carbon (DLC) or crystalline diamond coating.
Collapse
Affiliation(s)
- J R Montiès
- Laboratory for Surgical Research, Faculty of Medicine, Marseilles University, France
| | | | | | | | | | | |
Collapse
|
42
|
McCarthy PM, Young JB, Smedira NG, Hobbs RE, Vargo RL, Starling RC. Permanent mechanical circulatory support with an implantable left ventricular assist device. Ann Thorac Surg 1997; 63:1458-61. [PMID: 9146345 DOI: 10.1016/s0003-4975(97)00110-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
A 67-year-old man had end-stage ischemic cardiomyopathy. He had had two previous coronary bypass operations and a previous left ventricular aneurysmectomy. In December 1995 he underwent vented-electric HeartMate LVAD insertion as an alternative to transplantation. He was discharged from the hospital 13 days after the operation, and 5 months postoperatively he had returned to New York Heart Association functional class II.
Collapse
Affiliation(s)
- P M McCarthy
- Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, OH 44195, USA.
| | | | | | | | | | | |
Collapse
|
43
|
Abstract
BACKGROUND This study describes the present state of progress in the development of the Jarvik 2000 ventricular assist system. METHODS Designed for implantation in the human thorax, the system consists of a small (25 cm3, 90 g) intraventricular axial-flow blood pump that transmits power and data via internal electronics and a transcutaneous energy transfer system. The pump is powered by portable internal and external polymer lithium ion batteries. The only moving part, the pump rotor, contains a permanent magnet of a brushless direct-current motor that mounts an axial-flow impeller and partial magnetic thrust support, with blood-immersed radial and thrust bearings. The motor uses a redundant coil and electric lead design, which permits continued operation in case of wire breakage. RESULTS Seven calves have been supported for an average of 107 days (range, 40 to 162 days) with prototypes of the Jarvik 2000 ventricular assist system. No physiologic complications have occurred. When its user is at rest, the pump produces flows of 5 to 6 L/min with a decreased arterial pulse contour. Renal and hepatic functions have remained normal throughout the duration of all studies. Mean plasma free hemoglobin levels ranged from 4.3 to 11.4 mg/dL (mean, 6.3 mg/dL) for each study. Pathologic analyses of the heart and kidneys revealed no damage related to the device. CONCLUSIONS These studies indicate that the Jarvik 2000 ventricular assist system is feasible in animals and holds promise for long-term support of patients.
Collapse
Affiliation(s)
- M P Macris
- Cullen Cardiovascular Research Laboratories, Department of Cardiovascular Surgical Research, Texas Heart Institute, Houston 77030, USA
| | | | | | | | | |
Collapse
|
44
|
Takami Y, Otsuka G, Mueller J, Ohashi Y, Tayama E, Schima H, Schmallegger H, Wolner E, Nosé Y. Flow characteristics and required control algorithm of an implantable centrifugal left ventricular assist device. Heart Vessels 1997; 12:92-7. [PMID: 9403313 DOI: 10.1007/bf02820872] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
As the clinical application of LVADs has increased, attempts have been made to develop smaller, less expensive, more durable and efficient implantable devices using rotary blood pumps. Since chronic circulatory support with implantable continuous-flow LVADs will be established in the near future, we need to determine the flow characteristics through an implantable continuous-flow LVAD. This study describes the flow characteristics through an implantable centrifugal blood pump as a left ventricular assist device (LVAD) to obtain a simple non-invasive algorithm to control its assist flow rate adequately. A prototype of the completely seal-less and pivot bearing-supported centrifugal blood pump was implanted into two calves, bypassing from the left ventricle to the descending aorta. Device motor speed, voltage, current, flow rate, and aortic blood pressure were monitored continuously. The flow patterns revealed forward flow in ventricular systole and backward flow in diastole. As the pump speed increased, an end-diastolic notch became evident in the flow profile. Although the flow rate (Q [l/min]) and rotational speed (R [rpm]) had a linear correlation (Q = 0.0042R - 5.159; r = 0.96), this linearity was altered after the end-diastolic notch was evident. The end-diastolic notch is considered to be a sign of the sucking phenomenon of the centrifugal pump. Also, although the consumed current (I [A]) and flow rate had a linear correlation (I = 0.212Q + 0.29; r = 0.97), this linearity also changed after the end-diastolic notch was evident. Based upon the above findings, we propose a simple algorithm to maintain submaximal flow without inducing sucking. To maintain the submaximal flow rate without measuring flow rate, the sucking point is determined by monitoring consumed current according to gradual increases in voltage.
Collapse
Affiliation(s)
- Y Takami
- Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Moreno L, Leblanc M, Gurley M, Mccarthy P, Paganini EP. Dialytic Support in Patients with Acute Renal Failure with Implantable Left Ventricular Assist Devices. J Intensive Care Med 1997. [DOI: 10.1177/088506669701200104] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The left ventricular assist device (LVAD), used thus far as a bridge to heart transplantation, may offer an alternative to heart transplantation. Because patients receiving LVADs are in cardiogenic shock, many experience acute ischemic renal failure in the peri-implantation period. We describe 10 patients who underwent dialysis after receiving LVADs for end-stage heart disease. Among 37 patients who received an LVAD, 10 required dialytic support (8 men, 2 women; mean age, 47.3 ± 11.3 yr; mean APACHE II score at ICU admission, 18.0 ± 4.7). Renal replacement therapy was started for fluid removal within 48 hours of LVAD implantation in 8 patients. Continuous renal replacement therapy (CRRT) was the first-line modality for 9 patients, including 3 slow continuous ultrafiltrations (SCUF), 4 continuous venovenous hemofiltrations (CWH), 5 continuous venovenous hemodiafiltrations (CWHD), 2 continuous arteriovenous hemofiltrations (CAVH), and 1 continuous arteriovenous hemodiafiltration (CAVHD). Patients remained on CRRT for a mean of 14.4 ± 6.1 days, and 5 were eventually changed to intermittent hemodialysis. The mean time on renal replacement therapy was 27.8 ± 19.7 days. During CRRT, despite daily average ultrafiltration of 3,445 ± 623 mL, net fluid loss was only 358 ± 507 mL/day. Metabolic control achieved with CRRT, expressed as mean ± SD, was: BUN 75.5 ± 13.0 mg/dL (26.9 ± mmol/L), serum creatinine 4.0 ± 0.7 mg/dL (354 ± 62 mmol/L), carbon dioxide content (bicarbonate plus dissolved CO2) 21.5 ± 1.7 mEq/L, and serum electrolytes within normal limits. Survival for patients with LVADs who did not require dialysis was 93% compared with 40% for the group with combined LVADs and dialytic support. The 4 patients who survived in the dialysis group all recovered renal function, and their need for dialysis ceased within 18 to 33 days. Mean serum creatinine levels at follow-up after transplantation were 2.0 ± 1.0 mg/dL (177 ± 88 mmol/L). In conclusion, CRRT provides good metabolic control and allows large ultrafiltration volume in patients supported by an implantable LVAD. We observed a 40% survival rate in patients with combined LVADS and dialytic support, and the survivors all recovered renal function.
Collapse
Affiliation(s)
- Luz Moreno
- Cleveland Clinic Foundation, Cleveland, OH
| | | | | | | | | |
Collapse
|
46
|
Slater JP, Rose EA, Levin HR, Frazier OH, Roberts JK, Weinberg AD, Oz MC. Low thromboembolic risk without anticoagulation using advanced-design left ventricular assist devices. Ann Thorac Surg 1996; 62:1321-7; discussion 1328. [PMID: 8893563 DOI: 10.1016/0003-4975(96)00750-3] [Citation(s) in RCA: 107] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND A major limitation of cardiac assist devices has been the high incidence of thromboembolic events and their requirement for systemic anticoagulation. The Thermo Cardiosystems HeartMate 1000 IP left ventricular assist device (LVAD) employs a design that may reduce thromboembolic risk and obviate the need for systemic anticoagulation. METHODS Two hundred twenty-three patients with nonreversible heart failure were supported with the HeartMate LVAD as a bridge to heart transplantation. All patients were monitored prospectively for thromboembolic events. Anticoagulation regimens and occurrence of subclinical thromboembolic events, including those seen by transcranial Doppler examinations in selected patients, were also recorded. RESULTS Total time of LVAD support use was 531.2 patient-months. Twenty-three patients (10%) received warfarin postoperatively for 42.4 patient-months (8.2% of total support time). Six patients (2.7%) had thromboembolic events, representing 0.011 events per patient-month of device use. CONCLUSIONS The thromboembolic complication rate associated with this LVAD is acceptably low despite the minimal anticoagulation employed in this series, allowing consideration of long-term device use for the treatment of heart failure.
Collapse
Affiliation(s)
- J P Slater
- Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, USA
| | | | | | | | | | | | | |
Collapse
|
47
|
Spanier T, Oz M, Levin H, Weinberg A, Stamatis K, Stern D, Rose E, Schmidt AM. Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiovasc Surg 1996; 112:1090-7. [PMID: 8873737 DOI: 10.1016/s0022-5223(96)70111-3] [Citation(s) in RCA: 118] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Left ventricular assist devices have provided successful supportive therapy for patients awaiting cardiac transplantation for extended periods of time. Although thromboembolic events have complicated support with these devices, the HeartMate left ventricular assist device developed by Thermo Cardiosystems, Inc., Woburn, Massachusetts, was specifically designed with a textured blood-contacting surface to minimize this risk. Clinical experience with this device has been encouraging, inasmuch as minimal thromboembolic complications have occurred despite the absence of anticoagulation. The coagulation and fibrinolytic pathways in these individuals were investigated to better understand the hematologic status of patients treated with the Thermo Cardiosystems device. Despite apparently normal prothrombin and activated partial thromboplastin times, as well as platelet counts, evidence of significant thrombin generation and fibrinolysis was present. To eliminate underlying cardiac failure as the responsible factor for these abnormalities, we made similar measurements in patients with end-stage heart failure who were not supported by an assist device or anticoagulation. These measurements revealed no evidence of thrombin generation or fibrinolysis. These data demonstrate that patients supported with a left ventricular assist device, while successfully sustained without systemic anticoagulation, nevertheless have evidence of activation of coagulation. These phenomena appear to be related to the presence of the device rather than to the underlying cardiac abnormalities. Although procoagulant and fibrinolytic pathways are apparently balanced in these patients, these data underscore the potential for the development of bleeding or thrombosis in clinically relevant settings.
Collapse
Affiliation(s)
- T Spanier
- Department of Surgery, Columbia University College of Physicians and Surgeons, New York, N.Y. 10032, USA
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Abstract
Chronic immunosuppression, allograft coronary disease, and restricted availability of donor organs continue to limit the scope of cardiac transplantation. Meanwhile increasingly favourable experience with implantable blood pumps used as a bridge to transplant has reintroduced the concept of permanent mechanical cardiac support. Existing models (for example, the Thermo Cardiosystems Heartmate device) are now used for such support in patients who are not candidates for transplantation. Miniaturised axial flow pumps such as the Jarvik 2000 fit within the failed left ventricle and provide an exciting prospect for the treatment of heart failure in the future. Preliminary experience suggests that the "offloaded" left ventricle may recover. Mechanical blood pumps can be used before the onset of multisystem failure and removed if the myocardium recovers. This "bridge to recovery" concept should be tested in patients with recoverable cardiomyopathy and those with coronary disease and poor left ventricular function where an implantable pump can be used in conjunction with myocardial revascularisation.
Collapse
Affiliation(s)
- S Westaby
- Oxford Heart Centre, Oxford Radcliffe Hospital
| |
Collapse
|
49
|
Olivari MT. Cardiac transplantation: current indications, short-and long-term results, economic implications, and future developments. J Card Fail 1996; 2:141-52. [PMID: 8798116 DOI: 10.1016/s1071-9164(96)80033-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- M T Olivari
- University of Nebraska Medical Center, Department of Internal Medicine, Omaha 68198-2265 USA
| |
Collapse
|
50
|
Moulder PV, Findlay IS, Zone RM, Thompson AJ, Silber HA, Rank WR, Charbonnet MD, Webb WR, Harrison LH. Findlay Implantable Two-Stage Centrifugal Pump. Artif Organs 1996; 20:503-512. [PMID: 28868693 DOI: 10.1111/j.1525-1594.1996.tb04472.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
The Findlay centrifugal pump is unique in its two-stage pumping mechanisms and in its complementary interrelationship of the stages to each other and to the exit system, and it forms an extremely efficient unit. The first stage is a lift force pump as an inlet. The second and major stage is a shear force pump. Twenty-six prototypes, many multiply modified, have been hand fabricated, and most have had classic pump function analyses. Six pumps have demonstrated minimal hemolysis (3.5-5 h). At modest rotation speeds, it pumps water up to 10 L/min. Forty-four acute studies in normal dogs have been performed with the Findlay pump in a ventricular assist system. Blood flows through the pump ranged from 1.2 to 4.5 L/min. The conclusion is that the Findlay pump has the ability to operate with low blood damage, performs at acceptable rotational speed with reasonable hydraulic and mechanical efficiency, and is small and implantable.
Collapse
Affiliation(s)
- Peter V Moulder
- Louisiana State University and the New Orleans Veterans Administration Medical Center, Division of Cardiothoracic Surgery, U.S.ATulane University Department of Biomedical Engineering, U.S.AMid Continent Laboratories, New Orleans, LA, U.S.AVital Assist, Inc., New Orleans, LA, U.S.A
| | - Iain S Findlay
- Louisiana State University and the New Orleans Veterans Administration Medical Center, Division of Cardiothoracic Surgery, U.S.ATulane University Department of Biomedical Engineering, U.S.AMid Continent Laboratories, New Orleans, LA, U.S.AVital Assist, Inc., New Orleans, LA, U.S.A
| | - Robert M Zone
- Louisiana State University and the New Orleans Veterans Administration Medical Center, Division of Cardiothoracic Surgery, U.S.ATulane University Department of Biomedical Engineering, U.S.AMid Continent Laboratories, New Orleans, LA, U.S.AVital Assist, Inc., New Orleans, LA, U.S.A
| | - Arnold J Thompson
- Louisiana State University and the New Orleans Veterans Administration Medical Center, Division of Cardiothoracic Surgery, U.S.ATulane University Department of Biomedical Engineering, U.S.AMid Continent Laboratories, New Orleans, LA, U.S.AVital Assist, Inc., New Orleans, LA, U.S.A
| | - Harry A Silber
- Louisiana State University and the New Orleans Veterans Administration Medical Center, Division of Cardiothoracic Surgery, U.S.ATulane University Department of Biomedical Engineering, U.S.AMid Continent Laboratories, New Orleans, LA, U.S.AVital Assist, Inc., New Orleans, LA, U.S.A
| | - William R Rank
- Louisiana State University and the New Orleans Veterans Administration Medical Center, Division of Cardiothoracic Surgery, U.S.ATulane University Department of Biomedical Engineering, U.S.AMid Continent Laboratories, New Orleans, LA, U.S.AVital Assist, Inc., New Orleans, LA, U.S.A
| | - Michael D Charbonnet
- Louisiana State University and the New Orleans Veterans Administration Medical Center, Division of Cardiothoracic Surgery, U.S.ATulane University Department of Biomedical Engineering, U.S.AMid Continent Laboratories, New Orleans, LA, U.S.AVital Assist, Inc., New Orleans, LA, U.S.A
| | - Watts R Webb
- Louisiana State University and the New Orleans Veterans Administration Medical Center, Division of Cardiothoracic Surgery, U.S.ATulane University Department of Biomedical Engineering, U.S.AMid Continent Laboratories, New Orleans, LA, U.S.AVital Assist, Inc., New Orleans, LA, U.S.A
| | - Lynn H Harrison
- Louisiana State University and the New Orleans Veterans Administration Medical Center, Division of Cardiothoracic Surgery, U.S.ATulane University Department of Biomedical Engineering, U.S.AMid Continent Laboratories, New Orleans, LA, U.S.AVital Assist, Inc., New Orleans, LA, U.S.A
| |
Collapse
|